Product Pathways - Protein Stability
USP9X Antibody #5751
|5751S||100 µl (10 western blots)||---||In Stock||---|
|5751||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
|W||1:1000||Human, Mouse, Rat, Monkey, Dog||Endogenous||270||Rabbit|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting
Specificity / Sensitivity
USP9X Antibody recognizes endogenous levels of total USP9X protein. This antibody may also cross-react with USP9Y.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe2137 of human USP9X protein. Antibodies are purified by protein A and peptide affinity chromatography.
Protein ubiquitination and deubiquitination is a reversible process catalyzed by ubiquitinating enzymes (UBEs) and deubiquitinating enzymes (DUBs) (1,2). DUBs are categorized into five subfamiles-USP, UCH, OTU, MJD, and JAMM. USP9X/hFAM is an X-linked member of the ubiquitin-specific protease (USP) subfamily of DUBs and possesses a well-conserved catalytic domain with cysteine peptidase activity, which allows for cleavage of ubiquitin and polyubiquitin conjugates. USP9X is the mammalian homolog of the Drosophila fat-facets (faf) gene, which is essential for normal eye development and viability of the early fly embryo (3,4). While USP9X expression is also critical for normal mammalian development (5-7), many of its substrates are only beginning to be elucidated. There is mounting evidence that USP9X functions in the formation of cell-cell contacts during the polarization of epithelial cells, in part through deubiquitination-dependent stabilization of molecules involved in maintaining the integrity of both adherens and tight junctions. Indeed, USP9X has been found to associate with AF-6, the β-catenin-E-cadherin complex, and EFA6 (8-11). Studies have also demonstrated that USP9X is an integral component of the TGF-β/BMP signaling cascade and regulates TGF-β responsiveness by opposing TRIM33-mediated monoubiquitination of SMAD4 (12). Recently, USP9X was shown to be overexpressed in a variety of human cancers, which was linked to enhanced cell survival and chemoresistance through its ability to deubiquitinate and stabilize the Mcl-1 oncoprotein. This evidence supports USP9X as a therapeutic target in the context of human malignancies such as follicular lymphomas and diffuse large B-cell lymphomas (13).
- Nijman, S.M. et al. (2005) Cell 123, 773-86.
- Nalepa, G. et al. (2006) Nat Rev Drug Discov 5, 596-613.
- Huang, Y. et al. (1995) Science 270, 1828-31.
- Huang, Y. and Fischer-Vize, J.A. (1996) Development 122, 3207-16.
- Pantaleon, M. et al. (2001) Mech Dev 109, 151-60.
- Noma, T. et al. (2002) Mech Dev 119 Suppl 1, S91-5.
- Xu, J. et al. (2005) J Neurosci Res 80, 47-55.
- Taya, S. et al. (1998) J Cell Biol 142, 1053-62.
- Taya, S. et al. (1999) Genes Cells 4, 757-67.
- Murray, R.Z. et al. (2004) Mol Biol Cell 15, 1591-9.
- Théard, D. et al. (2010) EMBO J 29, 1499-509.
- Dupont, S. et al. (2009) Cell 136, 123-35.
- Schwickart, M. et al. (2010) Nature 463, 103-7.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.